Enzymatic Antibody Processing for Defined Glycostructures
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for downstream processing of recombinantly produced immunoglobulins fail to effectively remove (α1,3)glycosidically bound galactose residues, which can elicit an immune response in humans, and existing enzymes exhibit side reactivity or lack specificity with tri- or tetra-antennary oligosaccharides.
Innovation Solution
Employing (α1,3)galactosidases from plant origin, specifically from green coffee beans (EC 3.2.1.22), to selectively remove terminal galactose residues from the CH2 domain of immunoglobulins or immunoglobulin fragments, followed by affinity chromatography and protein A chromatography to produce immunoglobulins with defined glycostructures.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Object-affected harmful factors
If conventional chromatographic methods are used for downstream processing, then the process is simple and widely applicable, but the (α1,3)galactose residues cannot be removed
Solution Approach 1:
The patent replaces conventional mechanical/chromatographic separation methods with an enzymatic biological system. Specifically, it uses (α1,3)galactosidase enzyme to catalytically remove the harmful (α1,3)galactose residues from immunoglobulin glycostructures, transforming a physical separation problem into a biochemical transformation problem that achieves complete removal of the harmful substance.
Solution Approach 2:
The patent changes the chemical structure parameter of the glycostructure by introducing enzymatic hydrolysis. The (α1,3)galactosidase enzyme catalyzes the breakdown of the (α1,3)glycosidic bond, fundamentally altering the chemical structure of the harmful residue and converting it into removable fragments, thereby achieving complete elimination of the immunogenic component.
2Object-affected harmful factors
If enzymes with broad galactose removal capability are used, then the galactose content decreases, but side reactivity with other glycostructures occurs
Solution Approach 1:
The patent applies local quality by selecting an enzyme with highly specific substrate recognition. The (α1,3)galactosidase from green coffee beans has been characterized to recognize specifically the (α1,3)linked galactose configuration in the context of immunoglobulin Fc-region glycostructures, while avoiding reaction with other glycoforms such as (β1,4)linked galactose or galactose in different structural contexts, thus achieving selective removal.
Solution Approach 2:
The patent uses a well-characterized enzyme system from green coffee beans that has been extensively studied and its specificity profile mapped. By relying on this pre-characterized enzyme system with known specificities, the patent ensures reliable and selective removal of only the harmful (α1,3)galactose residues without unintended side reactions, effectively copying the success of previous enzymatic glycan modification approaches.
3Object-affected harmful factors
If specialized cell lines are developed to avoid galactose residues, then the immunogenicity is reduced, but the development time increases
Solution Approach 1:
The patent applies preliminary action by performing the galactose removal step during the downstream processing phase rather than requiring preventive measures during cell line development. The enzymatic treatment is applied to the crude or semi-purified immunoglobulin preparation after production, allowing the use of standard, well-established cell lines while still achieving the desired reduction in immunogenicity through post-production enzymatic modification.
Solution Approach 2:
The patent extracts the harmful (α1,3)galactose residues from the immunoglobulin glycostructures using enzymatic hydrolysis. By removing these harmful residues after production through enzymatic treatment, the patent eliminates the need to develop specialized cell lines that would otherwise be required to prevent their formation in the first place, thereby saving development time.
4Object-affected harmful factors
If existing (α1,3)galactosidases are used, then the galactose removal begins, but they lack specificity with tri- or tetra-antennary oligosaccharides
Solution Approach 1:
The patent changes the substrate specificity parameter of the enzyme by selecting (α1,3)galactosidase from green coffee beans, which has been characterized to recognize specifically the (α1,3)linked galactose configuration found in immunoglobulin Fc-region glycostructures. This enzyme variant maintains high activity toward the target substrate while showing reduced or no activity toward tri- or tetra-antennary oligosaccharides with different structural configurations, thereby achieving precise and selective glycostructure modification.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This method allows for the production of immunoglobulins with reduced immunogenicity by removing unwanted galactose residues, improving yield and product quality by converting all immunoglobulins to a defined glycostructure without removing desired glycoforms, thus avoiding the need for specialized cell lines and maintaining product quality.
Implementation Method 1
incubating the affinity chromatography column eluate with an enzyme, which cleaves off the terminal monosaccharide residues of the glycostructure in the CH2 domain of the immunoglobulin or immunoglobulin fragment
Implementation Method 2
an enzyme, which cleaves off the terminal monosaccharide residues of the glycostructure
Implementation Method 3
applying the incubated affinity chromatography eluate to a protein A chromatography material under conditions suitable for binding of the immunoglobulin or immunoglobulin fragment to the protein A chromatography material
Data Source
Figure 1
Figure 2
Figure 3
AI summary
The current invention comprises a method for producing an immunoglobulin or immunoglobulin fragment with defined glycostructure comprising the following steps: a) providing an affinity chromatography column eluate containing the immunoglobulin or immunoglobulin fragment, b) incubating the affinity chromatography column eluate with (a1,3)galactosidase of plant origin, e.g. from green coffee beans (EC 3.2.1.22), c) applying the incubated affinity chromatography column eluate to a protein A chromatography material and recovering the immunoglobulin or immunoglobulin fragment from the protein A chromatography material and thereby producing an immunoglobulin or immunoglobulin fragment with defined glycostructure.